24005-49-0Relevant academic research and scientific papers
Protein binding affinity of biologically active thiourea based half-sandwich Ru(II) cymene complexes
Mansour, Ahmed M.,Radacki, Krzysztof
, (2020)
Half-sandwich (η6-p-cymene) complexes bearing either neutral functionalized N,S-bidentate thiourea ligands or a mono-negative N,N-aminoquinoline ligand were screened for their antibacterial and antifungal activities as well as cell viability ag
Synthesis and evaluation of unsymmetrical heterocyclic thioureas as potent β-glucuronidase inhibitors
Taha, Muhammad,Ismail, Nor Hadiani,Jamil, Waqas,Khan, Khalid Mohammed,Salar, Uzma,Kashif, Syed Muhammad,Rahim, Fazal,Latif, Yawar
, p. 3166 - 3173 (2015/08/03)
Thiourea analogs 1-20 were synthesized and evaluated for their in vitro β-glucuronidase inhibitory potential. The compounds 9 (0.86 ± 0.01 μM), 6 (1.24 ± 0.01 μM), 16 (1.64 ± 0.02 μM) and 15 (2.12 ± 0.02 μM) showed potent activity. Other analogs 1-5, 7, 8
SUBSTITUTED QUINOLINE DERIVATIVES AS ANTIAMYLOIDOGENEIC AGENTS
-
Page/Page column 65, (2008/12/06)
The present invention relates to heterocyclic compounds, processes for their preparation and their use as pharmaceutical or veterinary agents, in particular for the treatment, amelioration and/or prophylaxis of conditions caused by or associated with unbalanced metal levels and/or oxidative stress, such as neurological conditions and cellular proliferative disorders, for example Alzheimer's disease, Parkinson's disease, Huntington's disease or brain cancer or tumours.
